Phase 2 Systemic Lupus Erythematosus trials recruiting now

All Systemic Lupus Erythematosus trials, every phase

Other phases for Systemic Lupus Erythematosus

Phase 2 Systemic Lupus Erythematosus trials

• A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
  NCT06106906 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
  NCT06106893 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
  NCT07509892 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 35 locations
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
  NCT07260877 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 32 locations
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 58 locations
• A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
  NCT07570862 · Phase: Phase 2 · Ages: 12 Years to 70 Years · Sex: All (male and female) · 9 locations
• A Study of E6742 in Participants With Systemic Lupus Erythematosus
  NCT07515014 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 54 locations
• A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
  NCT06535412 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
  NCT07299422 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
  NCT07598396 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  NCT07409181 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 140 locations
• Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
  NCT05029336 · Phase: Phase 2 · Ages: 8 Years to 25 Years · Sex: All (male and female) · 1 location
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  NCT06794008 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
  NCT06347718 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  NCT06350110 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
  NCT06434363 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 23 locations
• Safety of Administering Isoniazid to SLE Patients to Prevent TB
  NCT06618573 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 55 Years · Sex: Female · 1 location
• Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
  NCT06428188 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 90 Years · Sex: All (male and female) · 1 location
• Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
  NCT07657793 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
  NCT05440422 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.